2020 |
03/31 | 415 | 434 | 358 | 367 | -7.32% | 14,233,200 | 262億632万 | +19.54% |
03/30 | 15:00 再生医療向け臨床用iPS細胞の作製サービスの開始について |
03/30 | 10:00 新型コロナウイルス用ワクチンの開発を目指す国際的研究コンソーシアムへの参加について |
03/30 | 318 | 396 | 310 | 396 | +25.32% | 14,735,600 | 282億7712万 | +28.99% |
03/27 | 321 | 330 | 307 | 316 | -1.56% | 3,392,400 | 225億6457万 | +3.95% |
03/26 | 348 | 367 | 315 | 321 | +6.64% | 10,060,900 | 229億2161万 | +5.25% |
03/25 | 305 | 310 | 295 | 301 | +1.35% | 1,943,200 | 214億9347万 | -0.99% |
03/24 | 296 | 302 | 290 | 297 | +3.13% | 2,156,400 | 212億784万 | -2.62% |
03/23 | 303 | 303 | 286 | 288 | -5.26% | 2,007,200 | 205億6518万 | -5.26% |
03/19 | 319 | 322 | 292 | 304 | 0% | 2,545,400 | 217億769万 | -0.33% |
03/18 | 311 | 334 | 300 | 304 | -2.88% | 5,977,100 | 217億769万 | -0.65% |
03/17 | 250 | 324 | 250 | 313 | +20.85% | 8,955,600 | 223億5035万 | +2.29% |
03/16 | 15:00 当社と順天堂大学による共同事業のNEDO公募事業の助成期間延長決定および交付増額に関するお知らせ |
03/16 | 254 | 277 | 243 | 259 | +6.58% | 2,544,300 | 184億9438万 | -15.36% |
03/13 | 233 | 253 | 227 | 243 | -3.95% | 3,053,300 | 173億5187万 | -21.36% |
03/12 | 247 | 265 | 245 | 253 | -0.78% | 2,838,100 | 180億6594万 | -18.91% |
03/11 | 274 | 287 | 254 | 255 | -5.56% | 2,033,000 | 182億875万 | -19.05% |
03/10 | 250 | 273 | 238 | 270 | +1.5% | 3,829,600 | 192億7986万 | -15.09% |
03/09 | 295 | 298 | 260 | 266 | -13.07% | 3,258,800 | 189億9423万 | -17.13% |
03/06 | 302 | 317 | 301 | 306 | -0.97% | 1,759,400 | 218億5050万 | -5.56% |
03/05 | 324 | 325 | 305 | 309 | -2.22% | 1,877,400 | 220億6472万 | -5.79% |
03/04 | 302 | 322 | 302 | 316 | +0.96% | 1,525,700 | 225億6457万 | -3.95% |
03/03 | 331 | 333 | 309 | 313 | -0.63% | 2,274,200 | 223億5035万 | -3.99% |
03/02 | 297 | 325 | 296 | 315 | +6.06% | 3,452,300 | 224億9317万 | -2.17% |
02/28 | 317 | 327 | 293 | 297 | -10% | 4,641,200 | 212億784万 | -6.6% |
02/27 | 344 | 362 | 323 | 330 | -5.71% | 6,285,100 | 235億6427万 | +5.1% |
02/26 | 390 | 416 | 346 | 350 | -12.06% | 13,315,200 | 249億9241万 | +13.27% |
02/25 | 10:00 再生医療製品ステムカイマルの第II相臨床試験における第一例目の被験者への投与開始のお知らせ |
02/25 | 372 | 436 | 359 | 398 | +11.8% | 19,465,200 | 284億1994万 | +30.92% |
02/21 | 332 | 359 | 329 | 356 | +8.54% | 4,806,900 | 254億2085万 | +20.27% |
02/20 | 333 | 336 | 321 | 328 | 0% | 2,177,900 | 234億2146万 | +13.1% |
02/19 | 317 | 336 | 310 | 328 | +6.15% | 3,434,400 | 234億2146万 | +15.09% |
02/18 | 310 | 325 | 300 | 309 | -0.96% | 2,689,500 | 220億6472万 | +9.96% |
02/17 | 288 | 314 | 281 | 312 | +8.33% | 3,371,300 | 222億7894万 | +12.64% |
02/14 | 306 | 307 | 283 | 288 | -6.8% | 3,094,400 | 205億6518万 | +5.49% |
02/13 | 15:00 営業外収益・営業外費用及び特別損失の計上に関するお知らせ |
02/13 | 15:00 2020年3月期第3四半期決算短信〔日本基準〕(連結) |
02/13 | 314 | 315 | 306 | 309 | -0.96% | 1,372,500 | 220億6472万 | +14.87% |
02/12 | 309 | 323 | 305 | 312 | +0.32% | 2,108,800 | 222億7894万 | +17.74% |
02/10 | 320 | 320 | 303 | 311 | -3.12% | 2,410,000 | 222億754万 | +19.16% |
02/07 | 341 | 357 | 315 | 321 | -4.75% | 7,793,600 | 229億2161万 | +24.9% |
02/06 | 330 | 367 | 312 | 337 | +5.64% | 11,147,800 | 240億6412万 | +33.2% |
02/05 | 15:00 分担企業として参加するAMED公募事業の2018年度補助金交付額確定に関するお知らせ |
02/05 | 317 | 341 | 311 | 319 | +3.24% | 5,963,700 | 227億7879万 | +28.63% |
02/04 | 331 | 345 | 302 | 309 | -8.31% | 7,550,000 | 220億6472万 | +27.16% |
02/03 | 329 | 382 | 327 | 337 | -1.17% | 11,461,100 | 240億6412万 | +41% |
01/31 | 385 | 393 | 332 | 341 | -3.4% | 12,213,200 | 243億4974万 | +45.73% |
01/30 | 472 | 475 | 343 | 353 | -13.48% | 35,594,500 | 252億663万 | +54.15% |
01/29 | 400 | 408 | 392 | 408 | +24.39% | 5,265,900 | 291億3401万 | +82.14% |
01/28 | 285 | 328 | 281 | 328 | +32.26% | 11,074,400 | 234億2146万 | +51.85% |
01/27 | 214 | 266 | 212 | 248 | +20.39% | 13,654,300 | 177億890万 | +16.98% |
01/24 | 206 | 207 | 204 | 206 | -0.48% | 300,300 | 147億981万 | -2.37% |
01/23 | 209 | 209 | 206 | 207 | -0.96% | 247,700 | 147億8122万 | -1.9% |
01/22 | 209 | 210 | 208 | 209 | 0% | 131,200 | 149億2404万 | -1.42% |
01/21 | 208 | 211 | 208 | 209 | +0.48% | 192,400 | 149億2404万 | -1.88% |
01/20 | 208 | 209 | 206 | 208 | 0% | 175,800 | 148億5263万 | -2.8% |
01/17 | 208 | 209 | 206 | 208 | -0.48% | 199,800 | 148億5263万 | -3.26% |
01/16 | 212 | 212 | 207 | 209 | -0.95% | 235,000 | 149億2404万 | -2.79% |
01/15 | 209 | 212 | 207 | 211 | +0.48% | 276,500 | 150億6685万 | -2.31% |
01/14 | 211 | 212 | 208 | 210 | 0% | 159,400 | 149億9544万 | -2.78% |
01/10 | 210 | 213 | 210 | 210 | 0% | 154,400 | 149億9544万 | -3.23% |
01/09 | 205 | 211 | 205 | 210 | +2.94% | 275,100 | 149億9544万 | -3.67% |
01/08 | 207 | 207 | 202 | 204 | -1.92% | 561,800 | 145億6700万 | -6.85% |
01/07 | 208 | 209 | 207 | 208 | 0% | 155,400 | 148億5263万 | -5.45% |
01/06 | 207 | 209 | 206 | 208 | -1.42% | 277,400 | 148億5263万 | -5.88% |
2019 |
12/30 | 210 | 212 | 207 | 211 | -0.47% | 280,900 | 150億6685万 | -4.95% |
12/27 | 208 | 213 | 208 | 212 | +1.92% | 299,500 | 151億3826万 | -4.93% |
12/26 | 207 | 209 | 207 | 208 | +0.48% | 598,100 | 148億5263万 | -6.73% |
12/25 | 210 | 211 | 207 | 207 | -1.9% | 446,500 | 147億8122万 | -7.59% |
12/24 | 209 | 214 | 209 | 211 | +0.96% | 460,600 | 150億6685万 | -6.22% |
12/23 | 216 | 216 | 207 | 209 | -3.69% | 1,027,900 | 149億2215万 | -7.52% |
12/20 | 217 | 218 | 215 | 217 | 0% | 326,100 | 154億9334万 | -4.41% |
12/19 | 217 | 219 | 217 | 217 | -0.91% | 229,900 | 154億9334万 | -4.41% |
12/18 | 219 | 221 | 217 | 219 | 0% | 249,300 | 156億3613万 | -3.52% |
12/17 | 219 | 220 | 217 | 219 | +0.46% | 258,700 | 156億3613万 | -3.52% |
12/16 | 222 | 223 | 218 | 218 | -2.68% | 354,100 | 155億6474万 | -3.96% |
12/13 | 229 | 229 | 223 | 224 | -2.18% | 390,500 | 159億9312万 | -1.32% |
12/12 | 230 | 231 | 226 | 229 | -0.43% | 298,400 | 163億5240万 | +0.88% |
12/11 | 231 | 233 | 227 | 230 | +0.44% | 264,900 | 164億2381万 | +1.32% |
12/10 | 226 | 231 | 226 | 229 | +1.78% | 400,300 | 163億5240万 | +0.88% |
12/09 | 226 | 226 | 223 | 225 | +0.45% | 103,500 | 160億6677万 | -0.88% |
12/06 | 225 | 226 | 223 | 224 | -0.44% | 140,900 | 159億9536万 | -0.88% |
12/05 | 227 | 228 | 225 | 225 | -0.44% | 154,200 | 160億6677万 | -0.88% |
12/04 | 228 | 228 | 225 | 226 | -0.88% | 228,200 | 161億3818万 | -0.44% |
12/03 | 227 | 230 | 226 | 228 | -0.87% | 193,800 | 162億8099万 | +0.44% |
12/02 | 230 | 232 | 227 | 230 | +0.44% | 334,400 | 164億2381万 | +1.77% |
11/29 | 234 | 235 | 229 | 229 | -1.72% | 303,900 | 163億5240万 | +1.33% |
11/28 | 236 | 237 | 233 | 233 | -0.43% | 185,700 | 166億3803万 | +3.1% |
11/27 | 233 | 238 | 231 | 234 | 0% | 517,800 | 167億944万 | +4% |
11/26 | 232 | 234 | 231 | 234 | +0.86% | 219,900 | 167億944万 | +4% |
11/25 | 229 | 234 | 229 | 232 | +0.87% | 272,100 | 165億6663万 | +3.57% |
11/22 | 229 | 231 | 225 | 230 | +0.44% | 233,000 | 164億2381万 | +2.68% |
11/21 | 235 | 235 | 224 | 229 | -2.14% | 498,700 | 163億4130万 | +2.69% |
11/20 | 229 | 235 | 228 | 234 | +1.74% | 654,000 | 166億9809万 | +4.93% |
11/19 | 229 | 230 | 226 | 230 | +0.88% | 240,700 | 164億1265万 | +3.6% |
11/18 | 222 | 230 | 222 | 228 | +3.64% | 517,500 | 162億6994万 | +2.7% |
11/15 | 215 | 222 | 215 | 220 | +2.8% | 246,000 | 156億9906万 | -0.9% |
11/14 | 218 | 221 | 214 | 214 | -1.38% | 246,600 | 152億7090万 | -3.6% |
11/13 | 15:00 営業外費用の計上に関するお知らせ |
11/13 | 15:00 2020年3月期第2四半期決算短信〔日本基準〕(連結) |
11/13 | 222 | 222 | 215 | 217 | -2.25% | 340,000 | 154億8498万 | -2.25% |
11/12 | 15:00 再生医療製品ステムカイマルの第II相臨床試験に関する名古屋大学との治験契約締結のお知らせ |
11/12 | 223 | 224 | 220 | 222 | -0.89% | 176,300 | 158億4178万 | -0.45% |
11/11 | 223 | 224 | 222 | 224 | +0.9% | 96,300 | 159億8450万 | +0.45% |
11/08 | 226 | 228 | 222 | 222 | -1.77% | 203,900 | 158億4178万 | -0.89% |
11/07 | 15:00 A.N.H. Scientific Marketing Co.Ltd. とのタイにおける販売業務提携のお知らせ |
11/07 | 226 | 230 | 224 | 226 | +0.44% | 223,500 | 161億2722万 | +0.89% |
11/06 | 224 | 225 | 221 | 225 | +0.45% | 172,400 | 160億5586万 | +0.45% |
11/05 | 224 | 224 | 221 | 224 | +0.9% | 186,900 | 159億8450万 | 0% |
11/01 | 226 | 226 | 220 | 222 | -1.33% | 195,000 | 158億60万 | -0.89% |
10/31 | 226 | 228 | 225 | 225 | -0.88% | 217,100 | 160億1412万 | +0.45% |
10/24 | 15:00 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ |